Skip to main content
SpringerLink
Log in

Evaluation and Treatment of Insulin Resistance and Hyperglycemic States

  • Chapter
  • First Online:
Bariatric Endocrinology

  • 817 Accesses

Abstract

Hyperglycemic disorders are very common in patients with overweight or obesity. With increasing fat mass and the development of adiposopathy comes increasing risk of developing hyperglycemia. However, the prevalence of overweight or obesity is estimated at over 60% of the American population. Yet, type 2 diabetes mellitus affects only 16.4% of people with an extreme body mass index. The progression from lean and healthy to overweight or obesity with type 2 diabetes offers opportunities for diagnosing individuals at risk, and for treatment. Adiposopathy, which includes accrual of intra-abdominal adipose tissue and the development of an inflammatory milieu, promotes insulin resistance. Insulin resistance in turn leads to ineffective insulin activity and hyperglycemia. Prediabetes, defined as hyperglycemia, which does not meet thresholds for diabetes mellitus, already carries an increased risk of cardiovascular disease and death. The standard of care for patients with insulin resistance and hyperglycemic states is to aggressively modify all cardiovascular risk factors. At the same time, it is now also the standard of care to equally aggressively treat overweight, obesity, and adiposopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Reading List

  • Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130–9.

    Article  CAS  Google Scholar 

  • Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89(3):309–19.

    Article  Google Scholar 

  • ADA Standards of Medical Care in Diabetes—2016. Glycemic targets. Diabetes Care. 2016;39(Supplement 1):S39–46.

    Article  Google Scholar 

  • Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.

    Article  CAS  Google Scholar 

  • Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210–4.

    Article  CAS  Google Scholar 

  • Alexander CM, Landsman PB, Grundy SM. The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab. 2008;10(3):246–50.

    Article  CAS  Google Scholar 

  • Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368(17):1613–24.

    Article  CAS  Google Scholar 

  • American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38:S8–S16.

    Article  Google Scholar 

  • American Diabetes Association Standards of Medical Care in Diabetes—2016. Diabetes Care. 2016a;39(Supplement 1):1–203.

    Article  Google Scholar 

  • American Diabetes Association Standards of Medical Care in Diabetes—2016. Approaches to glycemic treatment. Diabetes Care. 2016b;39(Suppl 1):S52–9.

    Google Scholar 

  • Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.

    Article  CAS  Google Scholar 

  • Balkau B, Deanfield JE, Després JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation. 2007;116(17):1942–51.

    Article  Google Scholar 

  • Bays HE, Chapman RH, Grandy S, SHIELD Investigators’ Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5):737–47.

    Article  CAS  Google Scholar 

  • Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, et al. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract. 2008;62(10):1474–83. Epub 2008/08/07.

    Article  CAS  Google Scholar 

  • Belalcazar LM, Haffner SM, Lang W, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013;21:944–50.

    Article  CAS  Google Scholar 

  • Blüher M. Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? Clin Sci. 2016;130(18):1603–14.

    Article  Google Scholar 

  • Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [Erratum in Ann Intern Med 2007;147:887]. Ann Intern Med. 2007;147:386–99.

    Article  Google Scholar 

  • Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.

    Article  Google Scholar 

  • Buse JB, Bergenstal RM, Glass LC, et al. Use of twice daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–12.

    Article  Google Scholar 

  • Butler AE, Janson J, Bonner-Weir S, et al. β-cell deficit and increased apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.

    Article  CAS  Google Scholar 

  • Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89(3):335–45.

    Article  Google Scholar 

  • Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961–9.

    Article  CAS  Google Scholar 

  • Chen G, Shi L, Cai L, et al. Comparison of insulin resistance and β-cell dysfunction between the young and the elderly in normal glucose tolerance and prediabetes population: a prospective study. Horm Metab Res. 2016; https://doi.org/10.1055/s-0042–111325.

  • Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–6.

    Article  CAS  Google Scholar 

  • de Koning L, Merchant AT, Pogue J, et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007;28(7):850–6.

    Article  Google Scholar 

  • Devries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446–54.

    Article  CAS  Google Scholar 

  • Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96(6):1654–63.

    Article  CAS  Google Scholar 

  • Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166–73.

    Article  CAS  Google Scholar 

  • Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.

    Article  Google Scholar 

  • Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–14.

    Article  CAS  Google Scholar 

  • Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–84.

    Article  CAS  Google Scholar 

  • Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists/American College of Endocrinology’ comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438–47.

    Article  Google Scholar 

  • Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453–62.

    Article  CAS  Google Scholar 

  • Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.

    Article  CAS  Google Scholar 

  • Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended-release. Diabetes Care. 2014a;37:3309–16.

    Article  CAS  Google Scholar 

  • Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014b;37(4):912–21.

    Article  CAS  Google Scholar 

  • Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–103.

    Article  Google Scholar 

  • Gonzalez-Campoy JM. The birth of bariatric endocrinology and the coming of age of obesity medicine. US Endocrinol [Internet]. 2016;12(1):10–1. https://doi.org/10.17925/USE.2016.12.01.10.

    Article  Google Scholar 

  • Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/The American College of Endocrinology and The Obesity Society. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2013;19(0):1–82. Epub 2013/10/17.

    Google Scholar 

  • Gonzalez-Campoy JM, Richardson B, Richardson C, Gonzalez-Cameron D, Ebrahim A, Strobel P, et al. Bariatric endocrinology: principles of medical practice. Int J Endocrinol. 2014;2014:917813. Epub 2014/06/06.

    Article  Google Scholar 

  • Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8.

    Article  Google Scholar 

  • Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.

    Article  Google Scholar 

  • Guo F, Garvey WT. Development of a weighted cardiometabolic disease staging (CMDS) system for theprediction of future diabetes. J Clin Endocrinol Metab. 2015;100(10):3871–7.

    Article  CAS  Google Scholar 

  • Guo F, Garvey WT. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: stability of metabolic health status in adults. Obesity (Silver Spring). 2016;24(2):516–25.

    Article  Google Scholar 

  • Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014;22(1):110–8.

    Article  Google Scholar 

  • Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract. 2015;21(Suppl 1):1–87.

    Article  Google Scholar 

  • Herder C, Carstensen M, Ouwens DM. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab. 2013;15(Suppl 3):39–50.

    Article  CAS  Google Scholar 

  • Heymsfield SB, Peterson CM, Thomas DM, et al. Scaling of adult body weight to height across sex and race/ethnic groups: relevance to BMI. Am J Clin Nutr. 2014;100(6):1455–61.

    Article  CAS  Google Scholar 

  • Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.

    Article  CAS  Google Scholar 

  • Hollenbeck C, Reaven GM. Variations in insulin stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987;64(6):1169–73.

    Article  CAS  Google Scholar 

  • Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413–20.

    Article  CAS  Google Scholar 

  • Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004;109(6):706–13.

    Article  Google Scholar 

  • Kodama S, Horikawa C, Fujihara K, et al. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis. Am J Epidemiol. 2012;176(11):959–69.

    Article  Google Scholar 

  • Kodama S, Horikawa C, Fujihara K, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014;15(3):202–14.

    Article  CAS  Google Scholar 

  • Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23(11):1170–8.

    Article  CAS  Google Scholar 

  • Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27(4):978–83.

    Article  Google Scholar 

  • Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–8.

    Article  CAS  Google Scholar 

  • Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.

    Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER trial. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

    Article  CAS  Google Scholar 

  • Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12.

    Article  CAS  Google Scholar 

  • Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25:1123–8.

    Article  CAS  Google Scholar 

  • Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S9–S30.

    Article  CAS  Google Scholar 

  • Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192(1):211–7.

    Article  CAS  Google Scholar 

  • O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–36.

    Article  Google Scholar 

  • Obesity in Asia Collaboration. Is central obesity a better discriminator of the risk of hypertension than body mass index in ethnically diverse populations? J Hypertens. 2008;26(2):169–77.

    Article  Google Scholar 

  • Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011;95(5):875–92.

    Article  CAS  Google Scholar 

  • Reis JP, Allen N, Gunderson EP, et al. Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study. Obesity. 2015;23(4):879–85.

    Article  Google Scholar 

  • Rubino F, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77.

    Article  CAS  Google Scholar 

  • Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes Metab Syndr Obes. 2013;6:403–19.

    Article  Google Scholar 

  • Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.

    Article  CAS  Google Scholar 

  • Shah RV, Murthy VL, Abbasi SA, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. JACC Cardiovasc Imaging. 2014;7(12):1221–35.

    Article  Google Scholar 

  • Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793–801.

    Article  CAS  Google Scholar 

  • Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.

    Article  Google Scholar 

  • St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25(3):553–9.

    Article  CAS  Google Scholar 

  • The DPP Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program. Effect of lifestyle intervention and metformin. J Gerontol. 2006;61:1075–81.

    Article  Google Scholar 

  • Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233–44.

    Article  CAS  Google Scholar 

  • Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27(1):155–61.

    Article  CAS  Google Scholar 

  • Twig G, Afek A, Derazne E, et al. Diabetes risk among overweight and obese metabolically healthy young adults. Diabetes Care. 2014;37(11):2989–95.

    Article  CAS  Google Scholar 

  • van Dis I, Kromhout D, Geleijnse JM, et al. Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20,000 Dutch men and women aged 20–65 years. Eur J Cardiovasc Prev Rehabil. 2009;16(6):729–34.

    Article  Google Scholar 

  • Vazquez G, Duval S, Jacobs DR, et al. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev. 2007;29:115–28.

    Article  Google Scholar 

  • Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617–24.

    Article  Google Scholar 

  • Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–72.

    Article  Google Scholar 

  • Wilson PW, D’Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–72.

    Article  CAS  Google Scholar 

  • Wormser D, Kaptoge S, Di Angelantonio E, et al. Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–95.

    Google Scholar 

  • Zhang C, Rexrode KM, van Dam RM, et al. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008;117(13):1658–67.

    Article  Google Scholar 

  • Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Graduate School of Medicine, Mayo Clinic, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Rochester, MN, USA

    Daniel L. Hurley

  2. Endocrinology, Diabetes and Osteoporosis Clinic, Sterling, VA, USA

    Farhad Zangeneh

Authors
  1. Daniel L. Hurley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farhad Zangeneh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel L. Hurley .

Editor information

Editors and Affiliations

  1. MNCOME, Eagan, MN, USA

    J. Michael Gonzalez-Campoy

  2. Mayo Clinic, Rochester, MN, USA

    Daniel L. Hurley

  3. University of Alabama - Birmingham, Birmingham, AL, USA

    W. Timothy Garvey

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hurley, D.L., Zangeneh, F. (2019). Evaluation and Treatment of Insulin Resistance and Hyperglycemic States. In: Gonzalez-Campoy, J., Hurley, D., Garvey, W. (eds) Bariatric Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-95655-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95655-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95653-4

  • Online ISBN: 978-3-319-95655-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation